Attached files

file filename
EX-99.1 - PRESS RELEASE - Asterias Biotherapeutics, Inc.v384698_ex99-1.htm

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): July 24, 2014

 

Asterias Biotherapeutics, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   000-55046   46-1047971
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

230 Constitution Drive

Menlo Park, California 94025

(Address of principal executive offices)

 

(510) 521-3390

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

Forward-Looking Statements

 

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may, “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in Asterias’ periodic reports filed with the SEC under the heading “Risk Factors” and other filings that Asterias may make with the Securities and Exchange Commission. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, Asterias disclaims any intent or obligation to update these forward-looking statements.

 

This Report and any accompanying exhibits shall be deemed “furnished” and not “filed” under the Securities Exchange Act of 1934, as amended.

 

Section 7 - Regulation FD

 

Item 7.01 - Regulation FD Disclosure

 

On July 24, 2014, Asterias Biotherapeutics, Inc. issued the press release furnished as Exhibit 99.1, which is incorporated by reference.

 

Section 9 - Financial Statements and Exhibits

 

Item 9.01 - Financial Statements and Exhibits.

 

Exhibit Number Description
99.1 Press Release Dated July 24, 2014

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASTERIAS BIOTHERAPEUTICS, INC.  
       
       
Date: July 24, 2014 By: /s/ Robert W. Peabody  
    Chief Financial Officer  

 

 

2
 

 

Exhibit Number Description
99.1 Press Release Dated July 24, 2014

 

3